The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15831 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Claire Miller und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Food-Drug Interactions, Reducing Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Aims
This two‐part, adaptive study assessed the effect of food and an acid‐reducing agent (rabeprazole) on the pharmacokinetics (PK) and safety of capivasertib, a potent AKT inhibitor, in clinical development for cancer treatment.
Methods
In Part 1, healthy participants (n = 24) were randomized to receive single‐dose capivasertib after overnight fasting, a high‐fat, high‐calorie meal and with rabeprazole postovernight fasting in one of six treatment sequences. Based on Part 1 results, a new group of participants (n = 24) were randomized (Part 2) to receive capivasertib after overnight fasting, a low‐fat, low‐calorie meal and modified fasting (food restricted from 2 h before dosing to 1 h postdose) in one of six treatment sequences. Blood samples were collected for PK analyses.
Results
Following a high‐fat, high‐calorie meal, capivasertib exposure increased versus overnight fasting (geometric mean ratio [GMR] [90% confidence interval (CI)]: area under the concentration‐time curve [AUC inf ] 1.32 [1.22, 1.43], maximum concentration [ C max ] 1.23 [1.08, 1.41]), but was comparable to that postmodified fasting (GMR: AUC inf 1.13 [0.99, 1.29], C max 0.85 [0.70, 1.04]). AUC inf was similar and C max was lower with/without rabeprazole (GMR: AUC inf 0.94 [0.87, 1.02]), C max 0.73 [0.64, 0.84]). Capivasertib exposure was similar after a low‐fat, low‐calorie meal versus overnight fasting (GMR: AUC inf 1.14 [1.05, 1.25], C max 1.21 [0.99, 1.48]) or modified fasting (GMR: AUC inf 0.96 [0.88, 1.05], C max 0.86 [0.70, 1.06]). Safety was consistent with that in larger trials.
Conclusions
This study demonstrates that administering capivasertib with food or acid‐reducing agents does not lead to clinically relevant PK or safety profile changes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Late Developmental Oncology, AstraZeneca, Cambridge, UK.
- Oral Product Development, AstraZeneca, Macclesfield, UK.
- Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Förderung
- AstraZeneca
Zitieren
APA
Miller, C., Sommavilla, R., Murphy, D., Morris, T., Khatun, M., & Cullberg, M. (2023). The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15831
Vancouver
Miller C, Sommavilla R, Murphy D, Morris T, Khatun M, Cullberg M. The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15831
BibTeX
@article{Miller2023,
author = {Miller, Claire and Sommavilla, Roberto and Murphy, Donal and Morris, Thomas and Khatun, Mahmuda and Cullberg, Marie},
title = {The effect of food and acid‐reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15831}
}
EUVIMED